Content provided by peopleofpathology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by peopleofpathology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
Episode 201: Ashley Kalinauskas - How Torigen is Innovating Veterinary Oncology With Immunotherapy
MP3•Episode home
Manage episode 474361853 series 3385006
Content provided by peopleofpathology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by peopleofpathology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
My guest today is Ashley Kalinauskas, CEO of Torigen Pharmaceuticals.
What we discuss with Ashley:
- How her graduate research at Notre Dame led to the founding of Torigen Pharmaceuticals.
- Their approach provides an alternative to chemotherapy by using immunotherapy.
- The company aims to make cancer treatment more accessible and affordable for pet owners.
- Promising results have been seen in aggressive cancers like hemangiosarcoma.
- How Torigen is utilizing digital pathology with the Concentriq platform to improve cancer diagnostics.
- Torigen is conducting research into additional applications, including equine and exotic animal cancers.
- Studying spontaneous cancer in pets provides valuable insights for human oncology research.
- Veterinary immunotherapy advancements have the potential to influence human cancer treatments.
- Immunotherapy is playing an increasingly important role in both veterinary and human medicine.
Links for this episode:
Pathologists' Assistant Shadowing Network
People of Pathology Podcast:
204 episodes
MP3•Episode home
Manage episode 474361853 series 3385006
Content provided by peopleofpathology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by peopleofpathology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
My guest today is Ashley Kalinauskas, CEO of Torigen Pharmaceuticals.
What we discuss with Ashley:
- How her graduate research at Notre Dame led to the founding of Torigen Pharmaceuticals.
- Their approach provides an alternative to chemotherapy by using immunotherapy.
- The company aims to make cancer treatment more accessible and affordable for pet owners.
- Promising results have been seen in aggressive cancers like hemangiosarcoma.
- How Torigen is utilizing digital pathology with the Concentriq platform to improve cancer diagnostics.
- Torigen is conducting research into additional applications, including equine and exotic animal cancers.
- Studying spontaneous cancer in pets provides valuable insights for human oncology research.
- Veterinary immunotherapy advancements have the potential to influence human cancer treatments.
- Immunotherapy is playing an increasingly important role in both veterinary and human medicine.
Links for this episode:
Pathologists' Assistant Shadowing Network
People of Pathology Podcast:
204 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.